{"prompt": "['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', 'Efficacy Evaluation', 'Efficacy will be assessed by evaluating PASI, PPPASI, PGA,', 'dynamic PGA, H&F PGA, pustules count, VAS for pruritus / itch', 'and discomfort / pain on hands and feet, DLQI, and immunological', 'markers.', 'Safety and', 'Safety will be assessed by evaluating Adverse Events (AEs), vital', 'Tolerability', 'signs and physical examination.', 'Evaluation', 'Primary Endpoint', 'Percentage change from baseline in PPPASI after 20 weeks of', 'treatment with apremilast', 'Secondary', 'Absolute and percent change from baseline in PPPASI during', 'Enpoints', 'the 20 weeks treatment period', 'PPPASI 50 response and PPPASI 75 response, defined as a', '50% and 75% decrease in PPPASI from baseline, during the', '20 weeks treatment period', 'DLQI bands (0-1 no effect, 2-5 small effect, 6-10 moderate', 'effect, 11-20 very large effect, 21-30 extremely large effect on', 'the disease related quality of life) during the 20 weeks treatment', 'period', 'Absolute and percent change from baseline in DLQI during the', '20 weeks treatment period', 'Safety as assessed by AEs, vital signs and physical', 'examination', 'Exploratory', 'Absolute and percentage change from baseline in level of', 'Enpoints', 'immunological markers in plasma / serum during the 20 weeks', 'treatment period with apremilast', 'Percentage change from baseline in level of immunological', 'markers in skin biopsy samples after 20 weeks of treatment with', 'apremilast (sub-study)', 'Data Analysis /', 'This is a pilot study intended to gain first information on the possible', 'Statistical Methods', 'clinical and mechanistical effects of apremilast on PPP; therefore', 'the sample size is not based on statistical considerations.', 'The Full Analysis Set (FAS) is defined as all patients who received', 'at least one dose of study drug and the Per Protocol Set (PP) is', 'defined as all patients who received at least one dose of study drug', 'who completed the study with no major protocol violations. These', 'two analysis sets will be used for analyses of efficacy endpoints.', 'The definition of the PP set will be finalized in the data review', 'meeting prior to database closure.', 'In general, categorical variables will be summarized using', 'frequencies and percentages and continuous variables will be', 'summarized using number of observations, mean, standard', 'deviation, median, minimum, first quartile, third quartile, and', 'maximum.', 'The primary endpoint percent change from baseline in PPPASI', 'after 20 weeks of treatment will be summarized as continuous', 'variable together with 95%-confidence limits. Statistical', 'comparison between post- versus pre-treatment values will be', 'done based on the Wilcoxon signed-rank test with two-sided p-', 'value <0.05 indicating significance. Missing values will be replaced', 'Page 6 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', 'using ast-observation-carried-forward (LOCF) method for the', 'analysis of the primary endpoint based on the FAS.', 'Exploratory endpoints (plasma / serum immunological marker', 'analysis and the skin biopsy immunological marker (sub-study)) will', 'be analyzed outside of the study setting by a research laboratory', '(Psoriasis Research and Treatment Center, University Hospital', 'Charit\u00e9, Berlin, Germany). Statistical comparison between post-', 'versus pre-treatment values will be done based on the Wilcoxon', 'signed-rank test with two-sided p-value <0.05 indicating', 'significance.', 'Ethical', 'This study will be conducted in accordance with applicable laws', 'Considerations', 'and regulations including, but not limited to, the ICH E6 guideline', 'and the ethics principles that have their origins in the Declaration', 'of Helsinki. The independent ethics committee and the competent', 'authority must review and approve the study before any patients', 'are enrolled. Consent must be obtained from the patient using the', 'approved informed consent form (ICF) before any procedures', 'specified in the protocol are performed.', 'The data acquisition meets all requirements of data protection for', 'each individual patient, since all patient-related documentation can', 'only be identified by a patient identification number. All personal', 'information of the patient is accessible only to the treating', 'physician.', 'Page 7 of 75']\n\n###\n\n", "completion": "END"}